Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovit...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Saagar N., Camacci, Mona L., Bowie, Esther M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921955/
https://www.ncbi.nlm.nih.gov/pubmed/35350233
http://dx.doi.org/10.1159/000519275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921955/
https://www.ncbi.nlm.nih.gov/pubmed/35350233
http://dx.doi.org/10.1159/000519275

Ejemplares similares